By the numbers: Does circulating tumor cell enumeration have a role in metastatic breast cancer?

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3479-3483

  Liu, Minetta C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; FULVESTRANT; PACLITAXEL; ZOLEDRONIC ACID; TUMOR MARKER;

ADULT; ARTICLE; BONE METASTASIS; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CASE REPORT; CELL COUNTING; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIP PAIN; HUMAN; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; QUALITY OF LIFE; TREATMENT RESPONSE; WEIGHT BEARING; BLOOD; BONE NEOPLASMS; BREAST NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SECONDARY; TUMOR EMBOLISM;

BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; TUMOR MARKERS, BIOLOGICAL;

EID: 84911478430     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.6851     Document Type: Article

References (24)

1. Budd GT, Cristofanilli M, Ellis MJ, et al: Circulating tumor cells versus imaging: Predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:6403-6409, 2006
2. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al: Response rate accuracy in oncology trials: Reasons for interobserver variability-Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 15:3507-3514, 1997
3. Stearns V, Yamauchi H, Hayes DF: Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat 52:239-259, 1998
4. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
5. Ashworth TR: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 14:146-149, 1869
6. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897-6904, 2004
7. Lianidou ES, Markou A: Circulating tumor cells in breast cancer: Detection systems, molecular characterization, and future challenges. Clin Chem 57:1242-1255, 2011
8. Parkinson DR, Dracopoli N, Petty BG, et al: Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 10:138, 2012
9. Lin H, Balic M, Zheng S, et al: Disseminated and circulating tumor cells: Role in effective cancer management. Crit Rev Oncol Hematol 77:1-11, 2011
10. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004
11. Hayes DF, Cristofanilli M, Budd GT, et al: Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218-4224, 2006
12. Beveridge R: Circulating tumor cells in the management of metastatic breast cancer patients. Commun Oncol 4:79-82, 2007
13. De Giorgi U, Valero V, Rohren E, et al: Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27:3303-3311, 2009
14. De Giorgi U, Valero V, Rohren E, et al: Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Ann Oncol 21:33-39, 2010
15. Liu MC, Shields PG, Warren RD, et al: Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27:5153-5159, 2009
16. Nakamura S, Yagata H, Ohno S, et al: Multicenter study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 17:199-204, 2010
17. Nolé F, Munzone E, Zorzino L, et al: Variation of circulating tumor cell levels during treatment of metastatic breast cancer: Prognostic and therapeutic implications. Ann Oncol 19:891-897, 2008
18. Saad A, Kanate A, Sehbai A, et al: Correlation among [18F]fluorodeoxyglucose positron emission tomography/computed tomography, cancer antigen 27.29, and circulating tumor cell testing in metastatic breast cancer. Clin Breast Cancer 8:357-361, 2008
19. Cristofanilli M, Broglio KR, Guarneri V, et al: Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden. Clin Breast Cancer 7:471-479, 2007
20. Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420-1430, 2005
21. Jiang ZF, Cristofanilli M, Shao ZM, et al: Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): A multicenter, double-blind, prospective trial. Ann Oncol 24:2766-2772, 2013
22. Bidard FC, Mathiot C, Degeorges A, et al: Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol 21:1765-1771, 2010
23. Bidard FC, Peeters DJ, Fehm T, et al: Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol 15:406-414, 2014
24. Smerage JB, Barlow WE, Hortobagyi GN, et al: Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol [epub ahead of print on June 2, 2014]